Track 04: Toxoid Vaccines
Toxoid vaccinations are created utilizing a toxic substance (hurt) that has been made safe anyway that moves a safe response against the toxic substance. Rely upon the toxic substance made by explicit organisms (for example tetanus or diphtheria). The toxic substance assaults the circulatory framework and is, as it were, accountable for the reactions of the disease. The protein-based toxic substance is rendered harmless and used as the antigen in the inoculation to summon insusceptibility.
- CoV2 preS dTM-AS03 vaccine --Sanofi
- Zorecimeran (INN)
Related Conference of Track 04: Toxoid Vaccines
March 24-25, 2026
9th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
August 27-28, 2026
7th International conference on Vaccines, Vaccination and Immunization
Paris, France
Track 04: Toxoid Vaccines Conference Speakers
Recommended Sessions
- Track 01: Vaccines
- Track 02: Pediatric Vaccines
- Track 03: HIV Vaccines
- Track 04: Toxoid Vaccines
- Track 05: DNA & Synthetic Vaccines
- Track 06: Vaccines for Pregnant Women
- Track 07: Pediatric Vaccination
- Track 08: Zika Virus Vaccines
- Track 09: Vaccines for Unconventional Diseases
- Track 10: Vaccine Production & Development
- Track 11: Human Vaccines Against Infectious Diseases
- Track 12: Combination & Conjugate Vaccines
- Track 13: Vaccine Safety & Efficacy
- Track 14: Cancer, Malaria & TB Vaccines
- Track 15: RDT in Antibiotic Research
- Track 16: Side-effects of Vaccines
- Track 17: Vaccines Manufacturing Technologies
- Track 18: Vaccines Research and Clinical Trails
- Track 19: New Trends in Vaccines Development
Related Journals
Are you interested in
- Adjuvants and Immunopotentiators - VACCINE CONGRESS 2025 (Japan)
- Adult and Elderly Vaccination Strategies - VACCINE CONGRESS 2025 (Japan)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- AI and Data Science in Vaccine Discovery - VACCINE CONGRESS 2025 (Japan)
- Animal & Plant Derived Vaccines - Vaccines-Immunization-2026 (France)
- Animal Models & Clinical Trials - Vaccines-Immunization-2026 (France)
- Antibodies: Engineering & Therapeutics - Vaccines-Immunization-2026 (France)
- Antimicrobial Resistance and Vaccines - VACCINE CONGRESS 2025 (Japan)
- Booster Doses and Heterologous Vaccine Regimens - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - VACCINE CONGRESS 2025 (Japan)
- Cancer, Malaria & TB Vaccines - Vaccines-Immunization-2026 (France)
- Cellular Immunology & Latest Innovations - Vaccines-Immunization-2026 (France)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Combination & Conjugate Vaccines - Vaccines-Immunization-2026 (France)
- Corporate Innovation, Sponsorship & Exhibition - VACCINE CONGRESS 2025 (Japan)
- COVID-19 Vaccine Impact and Learnings - VACCINE CONGRESS 2025 (Japan)
- Current Research & Future Challenges - Vaccines-Immunization-2026 (France)
- DNA & Synthetic Vaccines - Vaccines-Immunization-2026 (France)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fish & Poultry Vaccines - Vaccines-Immunization-2026 (France)
- Geriatric Immunization - Vaccines-Immunization-2026 (France)
- Global Immunization Programs and Policy - VACCINE CONGRESS 2025 (Japan)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- HIV Vaccines - Vaccines-Immunization-2026 (France)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious Disease Vaccines - VACCINE CONGRESS 2025 (Japan)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Manufacturing, Supply Chain, and Distribution - VACCINE CONGRESS 2025 (Japan)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2025 (Japan)
- Next-Generation Vaccine Technologies - VACCINE CONGRESS 2025 (Japan)
- Paediatric Vaccination - Vaccines-Immunization-2026 (France)
- Pediatric and Neonatal Vaccines - VACCINE CONGRESS 2025 (Japan)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Travel & Edible Vaccines - Vaccines-Immunization-2026 (France)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Production & Development - Vaccines-Immunization-2026 (France)
- Vaccine Research Ethics and Regulations - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2025 (Japan)
- Vaccines - Vaccines-Immunization-2026 (France)
- Vaccines & Autism - Vaccines-Immunization-2026 (France)
- Vaccines against Drugs - Vaccines-Immunization-2026 (France)
- Vaccines against Infectious Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Immune Mediated Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Pregnant Women & Neonates - Vaccines-Immunization-2026 (France)
- Vaccines for Unconventional Diseases - Vaccines-Immunization-2026 (France)
- Vectors, Adjuvants & Delivery Systems - Vaccines-Immunization-2026 (France)
- Veterinary and Zoonotic Vaccines - VACCINE CONGRESS 2025 (Japan)
- Workshops and Poster Sessions - VACCINE CONGRESS 2025 (Japan)